Xenon Pharmaceuticals
XENE • NASDAQ
Xenon Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Ian C. Mortimer, with a market cap of $3.1B.
CEOIan C. Mortimer
Market Cap$3.1B
Biotechnology
Healthcare
Employees259.0
Websitexenon-pharma.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Xenon Pharmaceuticals
Date
Thursday, February 26, 2026 (in 2 weeks)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q4 2025
EPS Estimate
-$1.20
Earnings History
Past 12 earnings reports for Xenon Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 3, 2025 | Q3 2025 | -$1.15Est: -$1.16 | +0.9% | - | — |  10-Q |
| Aug 11, 2025 | Q2 2025 | -$1.07Est: -$1.00 | -7.0% | - | — | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.83Est: -$0.90 | +7.8% | $7.5MEst: $1.9M | +292.7% | 10-Q |
| Feb 27, 2025 | Q4 2024 | -$0.84Est: -$0.84 | 0.0% | -Est: $312.5K | -100.0% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.81Est: -$0.81 | 0.0% | - | — | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.75Est: -$0.70 | -7.1% | - | — | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.62Est: -$0.66 | +6.1% | - | — | 10-Q |
| Feb 29, 2024 | Q4 2023 | -$0.64Est: -$0.76 | +15.8% | -Est: $1.9M | -100.0% | 10-K |
| Nov 8, 2023 | Q3 2023 | -$0.73Est: -$0.77 | +5.2% | -Est: $1.5M | -100.0% | — |
| Aug 9, 2023 | Q2 2023 | -$0.72Est: -$0.70 | -2.9% | -Est: $400.0K | -100.0% | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.63Est: -$0.62 | -1.6% | -Est: $570.0K | -100.0% | 10-Q |
| Mar 1, 2023 | Q4 2022 | -$0.57Est: -$0.58 | +1.7% | -Est: $2.3M | -100.0% | — |